Amended Claims (Attorney Docket No. BHC 032011)

1. (Currently amended) An A urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

-X- represents <u>a</u> bond, -O- or -N(\mathbb{R}^{10})- (wherein \mathbb{R}^{10} is hydrogen or $\mathbb{C}_{1.6}$ alkyl); with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

or

R^A and R^B together form a carbonyl-group with the carbon-atom to which they are connected,

R¹ represents aryl or heteroaryl

wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C_{1-6} alkylamino, $di(C_{1-6}$ alkyl)amino, C_{3-8} cycloalkylamino, C_{1-6} alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C_{1-6} alkylamino, $di(C_{1-6}$ alkyl)amino, C_{3-8} cycloalkylamino, or C_{1-6} alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C_{1-6} alkylamino, $di(C_{1-6}$ alkyl) amino, C_{3-8} cycloalkylamino, or C_{1-6} alkoxycarbonyl), sulfonamide, C_{1-6} alkanoyl, C_{1-6} alkanoylamino, carbamoyl, C_{1-6} alkylcarbamoyl, cyano, C_{1-6} alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C_{1-6} alkoxycarbonyl

or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃ cycloalkyl, and heterocycle; and

 $R^2 \qquad \text{represent C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, hydrogen, hydroxy,} \\ \qquad \text{aryl, heteroaryl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,} \\$

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{3-8} cycloalkyl, amino, N-(C_{1-6} alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C_{1-6} alkyl)aminocarbonyl, or N,N,-di(C_{1-6} alkyl)-aminocarbonyl, and

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, $(C_{1-6}alkoxy)$ carbonyl, C_{3-8} cycloalkyl, amino, N- $(C_{1-6}alkyl)$ amino, N,N-di $(C_{1-6}alkyl)$ amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N- $(C_{1-6}alkyl)$ aminocarbonyl, N,N-di $(C_{1-6}alkyl)$ -aminocarbonyl, $C_{1-6}alkyl$ optionally substituted by mono-, di-, or tri-halogen, or $C_{1-6}alkoxy$ optionally substituted by mono-, di-, or tri-halogen.

2. (Currently amended) An The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- m represents 0, 1, 2, or 3;
- p represents 0, 1, 2, or 3;
- -X- represents <u>a</u> bond, -O- or -N(R^{10})- (wherein R^{10} is hydrogen or C_{1-6} alkyl);

Atty. Docket No.: BHC 032011

with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

R¹ represents aryl or heteroaryl

wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6 alkyl) amino, C3-8 cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C3. 8 cycloalkyl, and heterocycle; and

 R^2 represent C_{1-6} alkylcarbonyl, C_{1-6} alkylsulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{3-8} cycloalkyl, amino, N-(C_{1-6} alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C_{1-6} alkyl)aminocarbonyl, or N,N,-di(C_{1-6} alkyl)-aminocarbonyl, and

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, $(C_{1-6}alkoxy)$ carbonyl, C_{3-8} cycloalkyl, amino, N- $(C_{1-6}alkyl)$ amino, N,N-di $(C_{1-6}alkyl)$ amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)aminocarbonyl, N,N-di(aryl)-aminocarbonyl, C₁₋₆alkyl optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆alkoxy optionally substituted by mono-, di-, or tri-halogen.

3. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- m represents 0, 1, 2, or 3;
- p represents 0, 1, 2, or 3;
- -X- represents <u>a</u> bond, -O- or -N(R^{10})- (wherein R^{10} is hydrogen or C_{1-6} alkyl); with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl) amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆

alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃. 8 cycloalkyl, and heterocycle; and

R² represent C_{1-6} alkylcarbonyl, C_{1-6} alkylsulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{3-8} cycloalkyl, amino, N-(C_{1-6} alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C_{1-6} alkyl)aminocarbonyl, or N,N,-di(C_{1-6} alkyl)-aminocarbonyl, and

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, $(C_{1-6}alkoxy)$ carbonyl, C_{3-8} cycloalkyl, amino, N- $(C_{1-6}alkyl)$ amino, N,N-di $(C_{1-6}alkyl)$ amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N- $(C_{1-6}alkyl)$ aminocarbonyl, N,N-di $(C_{1-6}alkyl)$ aminocarbonyl, $C_{1-6}alkyl$ optionally substituted by mono-, di-, or tri-halogen, or $C_{1-6}alkoxy$ optionally substituted by mono-, di-, or tri-halogen.

4. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- m represents 0, 1, 2, or 3;
- p represents 0, 1, 2, or 3;
- -X- represents <u>a</u> bond, -O- or -N(\mathbb{R}^{10})- (wherein \mathbb{R}^{10} is hydrogen or \mathbb{C}_{1-6} alkyl); with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃. 8 cycloalkyl, and heterocycle; and

R² represent C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, hydrogen, hydroxy, phenyl, naphthyl, pyridyl, or pyrimidyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, phenysulfonyl, pyrimidylsulfonyl, or pyridylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{3-8} cycloalkyl, amino, N-(C_{1-6} alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C_{1-6} alkyl)aminocarbonyl, or N,N,-di(C_{1-6} alkyl)-aminocarbonyl, and

said cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, phnyl moiety, pyridyl moiety or pyrimidyl moiety of said phenylsulfonyl, pyridylsulfonyl, pyrimidylsulfonyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, $(C_{1-6}alkoxy)$ carbonyl, C_{3-8} cycloalkyl, amino, N- $(C_{1-6}alkyl)$ amino, N,N-di $(C_{1-6}alkyl)$ amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)amino, N-(aryl)aminocarbonyl, N,N-di(aryl)-aminocarbonyl, C₁₋₆alkyl optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆alkoxy optionally substituted by mono-, di-, or tri-halogen.

5. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- m represents 0, 1, 2, or 3;
- p represents 0;
- -X- represents <u>a</u> bond;

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃. g cycloalkyl, and heterocycle; and

R² represent C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, hydrogen, hydroxy,

phenyl, naphthyl, pyridyl, 01 pyrimidyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,

C₃₋₈cycloalkyl, phenysulfonyl, pyrimidylsulfonyl, or pyridylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{3-8} cycloalkyl, amino, N-(C_{1-6} alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C_{1-6} alkyl)aminocarbonyl, or N,N,-di(C_{1-6} alkyl)-aminocarbonyl, and

said cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, phnyl moiety, pyridyl moiety or pyrimidyl moiety of said phenylsulfonyl, pyridylsulfonyl, pyrimidylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, $(C_{1-6}alkoxy)$ carbonyl, C_{3-8} cycloalkyl, amino, N- $(C_{1-6}alkyl)$ amino, N,N-di $(C_{1-6}alkyl)$ amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N- $(C_{1-6}alkyl)$ aminocarbonyl, N,N-di $(C_{1-6}alkyl)$ -aminocarbonyl, $C_{1-6}alkyl$ optionally substituted by mono-, di-, or tri-halogen, or $C_{1-6}alkoxy$ optionally substituted by mono-, di-, or tri-halogen.

6. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- m represents 1, 2, or 3;
- p represents 0, 1, 2, or 3;
- -X- represents a bond, -O- or -N(R^{10})- (wherein R^{10} is hydrogen or C_{1-6} alkyl);
- R^A and R^B represent hydrogen,
- R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl, wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C3. 8 cycloalkyl, and heterocycle; and

R² represent C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, hydrogen, hydroxy, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, <u>or</u> C₃₋₈cycloalkyl,

wherein

said alkyl, alkenyl, cycloalkyl, or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁₋₆alkoxy, C₁₋₆alkoxycarbonyl, C₃₋₈cycloalkyl, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆alkyl)aminocarbonyl, or N,N,-di(C₁₋₆alkyl)-aminocarbonyl.

7. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- m represents 0;
- p represents 0;

Bouchon, et al. Atty. Docket No.: BHC 032011

-X- represents -O- or -N(R^{10})- (wherein R^{10} is hydrogen or C_{1-6} alkyl); R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C_{1.6} alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃. 8 cycloalkyl, and heterocycle; and

 R^2 represent C_{1-6} alkylcarbonyl, C_{1-6} alkylsulfonyl, hydrogen, hydroxy, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-8} cycloalkyl,

wherein

said alkyl, alkenyl, cycloalkyl, or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{3-8} cycloalkyl, amino, $N-(C_{1-6}$ alkyl)amino, $N-(C_{1-6}$ alkyl)amino, $N-(C_{1-6}$ alkyl)amino, or $N-(C_{1-6}$ alkyl)aminocarbonyl, or $N-(C_{1-6}$ alkyl)aminocarbonyl.

8. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 1, 2, or 3;

p represents 0, 1, 2, or 3;

-X- represents a bond, -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃-8 cycloalkyl, and heterocycle; and

- R^2 represent hydrogen, hydroxy, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-8} cycloalkyl, C_{3-8} cycloalkyl, C_{3-6} alkynyl, or C_{3-8} cycloalkyl, C_{3-6} cycloalkyl, C_{3-6} alkynyl, or C_{3-8} cycloalkyl, C_{3-6} alkynyl, or C_{3-8} cycloalkyl, C_{3-6} alkynyl, or C_{3-8} cycloalkyl, C_{3-8} cycloalkyl, C
- 9. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

Atty. Docket No.: BHC 032011

Bouchon, et al.

wherein said phenyl, naphthyl, pyridyl, or pyrimidyl is optionally substituted by one or more of substituents selected from the group consisting of chloro, bromo, fluoro, nitro, methoxy, trifluoromethyl, trifluoromethoxy and C_{1-6} alkanoylamino.

10. (Currently amended) The urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said urea derivative of the formula (I) is selected from the group consisting of:

N-(4-chlorophenyl)-N'-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-hydroxy-1,2,3,4-tetrahydroquinolin-5-yl)urea;

ethyl 3-({[(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin- 5-yl)amino]carbonyl}amino)-benzoate; and

N-biphenyl-3-yl-N'-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea-,

and

the salts thereof.

- 11. (Currently amended) A medicament pharmaceutical composition comprising the tetrahydroquinolinylurea a urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.
- 12. (Currently amended) The medicament pharmaceutical composition as claimed in claim 11, further comprising one or more pharmaceutically acceptable excipients.
- 13. (Currently amended) The medicament pharmaceutical composition as claimed in claim 11, wherein said tetrahydro quinolinylurea urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.
- 14. (Currently amended) The medicament as claimed in claim 11 A method for the treatment and/or prevention of an urological disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.

Bouchon, et al. Atty. Docket No.: BHC 032011

15. (Currently amended) The medicament method as claimed in claim 14, wherein said urological disorder or disease is detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and or lower urinary tract symptoms.

- 16. (Currently amended) The medicament as claimed in claim 11 A method for the treatment and/or prevention of pain comprising administering to a subject in need thereof a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
- 17. (Currently amended) The medicament method as claimed in claim 16, wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.
- 18. (Currently amended) The medicament as claimed in claim 11 A method for the treatment and/or prevention of a disorder or disease related to pain comprising administering to a subject in need thereof a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
- 19. (Currently amended) The <u>medicament method</u> as claimed in claim 18, wherein said disorder or disease <u>realted related</u> to pain is neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.
- 20. (Currently amended) The medicament as claimed in claim 11 A method for the treatment and/or prevention of an inflammatory disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
- 21. (Currently amended) The medicament method as claimed in claim 20, wherein said inflammatory disorder or disease is asthma or COPD.
- 22. (Cancelled).
- 23. (Cancelled).

Bouchon, et al. Atty. Docket No.: BHC 032011

- 24. (Cancelled).
- 25. (Cancelled).
- 26. (Cancelled).
- 27. (Cancelled).